Information  X 
Enter a valid email address

Silence Therapeutics (SLN)

  Print      Mail a friend

Friday 15 June, 2018

Silence Therapeutics

Presents Data on Lead Programme SLN124 at EHA

RNS Number : 4680R
Silence Therapeutics PLC
15 June 2018


Silence Therapeutics Presents Data on Lead Programme SLN124 at 23rd Annual European Hematology Association Congress


15 June 2018


Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces today it will be presenting data on its siRNA conjugate technology and lead candidate SLN124, for the treatment of iron overload disorders at the 23rd Annual European Hematology Association (EHA) Congress held on 14-17 June, 2018 at Stockholmsmässan: Mässvägen 1, 125 80 Älvsjö, Sweden.


Dr Ute Schaeper, Drug Discovery Project Leader, will give an oral presentation (S893) entitled "Development of a GalNAc-siRNA Conjugate Targeting TMPRSS6 for the Treatment of Iron Overload Disorders, such as Beta-Thalassemia" on Saturday, 16 June at 16:30 CEST. The presentation will be part of the 'Iron: From basic science to clinical application' session held in Room A13.


The data to be presented demonstrate that GalNAc-siRNA conjugate SLN124 is a promising candidate for the treatment of iron overload and anaemia in Beta-Thalassemia and related disorders. SLN124 is undergoing preclinical development and is planned to enter the clinic in 2019.


Dr Ute Schaeper, Drug Discovery Project Leader at Silence Therapeutics, commented: "Our studies demonstrate that GalNAc-conjugated siRNA designed to silence TMPRSS6 in hepatocytes may provide a safe, effective and patient-friendly therapeutic option for the treatment of iron overload disorders. SLN124 shows dose-dependent and long-lasting effects on target levels as well as on modulation of iron stores and normalisation of erythropoiesis in relevant disease models. We believe that SLN124's mechanism of action and profile will potentially deliver an improved approach to patients in need."


The presentation will be available on the Company's website:


To view the full abstract; please visit





Silence Therapeutics plc

Annalisa Jenkins, Executive Chair

David Ellam, Chief Financial Officer



Tel: +44 (0) 20 3457 6900

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel/ Oliver Jackson


Tel: +44 (0) 20 7418 8900

Media & IR Enquiries

Optimum Strategic Communications 

Mary Clark/ Eva Haas/ Hollie Vile

[email protected]


Tel: +44 (0) 20 3714 1788

IR Enquiries - US

Burns McClellan

John Grimaldi

[email protected]


Tel: +1 (212) 213 0006

Notes to Editors


About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit:


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t